Tekmira alleges that Alnylam has, among other things, illegally used its proprietary technology to develop new versions of lipid nanoparticle delivery agents.
Alnylam said that as part of the agreement, it would allow Merck, the parent company of one-time rival Sirna Therapeutics, to sub-license a portion of the disputed IP to which it previously did not have access.
In making its decision, the court said that Mirinia has “raised only serious questions” on the merits of its trademark infringement claim, and not shown that it would suffer “irreparable harm” if Marina is allowed to continue using its newly acquired moniker.
Signal filed its suit against Med BioGene earlier this month alleging a breach of agreement, violation of a confidentiality agreement, and misuse of proprietary information, among other charges.
Signal has alleged that Med BioGene breached the provisions in a term sheet inked between the two companies regarding an exclusive, worldwide license for Med BioGene's LungExpress Dx test.
The action is an amendment to a lawsuit in which plaintiffs argued that the company, its board, and certain of its officers breached their fiduciary duty in connection to the company's trouble with its Accutn1 troponin test last year.
As a result, it will be up to the new court to rule on CSHL's allegations that the law firm Ropes & Gray mishandled certain RNAi-related intellectual property stemming from the work of Greg Hannon and maintained improper business relationships with RNAi drug developers.
As part of a lawsuit seeking control of the technology, Santaris has successfully petitioned the European Patent Office to stay its review of Mirrx's patent application.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
